SAMe supplement to prevent liver cancer in cirrhosis
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests whether a daily supplement called SAMe can help prevent liver cancer in people with cirrhosis caused by a condition called MASLD (fatty liver disease). If you have cirrhosis from fatty liver, this study may offer a way to reduce your risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with MASLD (fatty liver disease) and have at least one related condition like being overweight, having diabetes or prediabetes, high blood pressure, or abnormal cholesterol.
- You have cirrhosis confirmed by a liver biopsy or by imaging tests like FibroScan, CT, MRI, or ultrasound.
- You drink less than about 7 drinks per week (men) or 4 drinks per week (women).
- You have had a liver cancer screening test (ultrasound, MRI, or CT) within the last 3 months.
- You do not have other liver diseases like hepatitis B or C, and you are not pregnant or nursing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding navy beans to your regular diet can reduce liver fat and improve liver health in people with a type of fatty liver disease called MASLD. You'll eat beans daily for several months and attend regular checkups, including MRI scans and blood tests.
This Phase 2 study tests whether SAMe can help people with alcoholic cirrhosis (scarred liver) who are in early to mid stages. It may also include healthy volunteers to compare safety and blood/body measurements.
This study tests whether aspirin can help people with MASLD, a type of fatty liver disease linked to conditions like diabetes and obesity. It aims to see if aspirin can improve liver health without causing harm.
This study aims to understand the genetic factors behind metabolic fatty liver disease (MASLD) by comparing patients with advanced liver scarring or liver cancer to healthy blood donors. It may help doctors better predict and treat the disease in the future.
This study looks at whether breast or colorectal cancer survivors are more likely to develop a liver condition called MASLD (fatty liver disease not caused by alcohol). It uses blood tests, imaging, and possibly an MRI to check liver health.
This study looks at factors that predict liver cancer and the need for a liver transplant in people with a liver condition called MASLD (metabolic dysfunction-associated steatotic liver disease). The goal is to better understand the disease and improve care.
Hear when a new Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.